Status:
COMPLETED
Predicting the Diagnosis of Asthma
Lead Sponsor:
University of South Florida
Conditions:
Asthma
Eligibility:
All Genders
18-64 years
Brief Summary
Despite the development of effective medications for treatment, asthma remains a significant contributor of morbidity, mortality, and financial hardship to patients with the disease. An estimated 300 ...
Eligibility Criteria
Inclusion
- 18-64 years of age at enrollment
- Literacy: The subject must be able to read, comprehend, and record information in English.
- Consent: The subject must have the ability to give informed consent.
- Type of subject: The subject must be seen in the outpatient setting.
Exclusion
- Respiratory Instability: Hospitalization for respiratory disease within the last 6 months during study period and prior to Visit 0.
- Respiratory Disease: Current diagnosis of cystic fibrosis, pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, or any other lower respiratory abnormalities other than asthma.
- Prior Treatment of Asthma: Treatment for asthma with any medication (except for short acting inhaled bronchodilators) for 12 months or more prior to Visit 0
- Drug Allergy: Any immediate or delayed hypersensitivity reaction to any beta2-agonist or sympathomimetic drug
- Respiratory Tract Infections: Confirmed or suspected infection of the sinus, middle ear, oropharynx, upper respiratory tract, or lower respiratory tract within 28 days prior to testing
- Other Concurrent Conditions/Diseases: Any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbates during the study. The list of conditions/diseases that will result in exclusion if determined to be clinically significant includes, but is not limited to: cardiac arrhythmia, congestive heart failure, coronary artery disease, Addison's disease, diabetes mellitus, dyspnea by any cause other than asthma, uncontrolled hypertension, hematological, hepatic, neurological, thyroid, peptic ulcer, or renal disease, immunologic compromise, current malignancy, current or quiescent tuberculosis.
- Concomitant Medications:
- Beta blockers
- Systemic corticosteroids
- Angiotensin Converting Enzyme (ACE) inhibitors (Note: Immunotherapy for the treatment of allergies is allowed, provided that the subject has received a constant dose for 30 days prior to Visit 0, and that the same dose will continue throughout the study.)
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00620334
Start Date
February 1 2007
End Date
June 1 2008
Last Update
August 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
USF
Tampa, Florida, United States, 33613